Clinical Trial Update: Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and immunogenicity of repeated doses of ABvac40 in adults with Mild Cognitive Impairment or Alzheimer Disease; results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• ABvac40

Snippet

Sponsor: Araclon Biotech S.L. | Conditions: Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-02-03